Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 5/20 | 0.35 |
| ▸ | MTTP | P55157 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447659 | 0.93 | CCR1 (0.39) | FPR2F10CCR1KCNH2RAB9A | |
| SCHEMBL3449332 | 0.91 | CCR3 (0.38) | FPR2MEN1KMT2AF10CCR1 | |
| SCHEMBL3450668 | 0.90 | CCR1 (0.44) | FPR2F10CCR1MAPTNPC1 | |
| SCHEMBL3449677 | 0.90 | CCR1 (0.44) | FPR2F10CCR1MAPTNPC1 | |
| SCHEMBL3452013 | 0.90 | F10 (0.38) | FPR2F10CCR1 | |
| SCHEMBL3451848 | 0.90 | CCR1 (0.44) | FPR2F10CCR1MAPTNPC1 | |
| SCHEMBL3447685 | 0.90 | FPR2 (0.45) | FPR2MEN1KMT2AF10 | |
| SCHEMBL3449116 | 0.89 | MEN1 (0.40) | FPR2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL3451846 | 0.89 | EPHX2 (0.44) | MTTP | |
| SCHEMBL3448955 | 0.88 | EP300 (0.38) | FPR2MEN1KMT2AF10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | FPR2 417/4885SIGMAR1 78/4885POLB 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.